[{"orgOrder":0,"company":"Xediton Pharmaceuticals","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Licensing Agreement","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Xediton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xediton Pharmaceuticals \/ Xediton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Xediton Pharmaceuticals \/ Xediton Pharmaceuticals"},{"orgOrder":0,"company":"Xediton Pharmaceuticals","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Xediton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xediton Pharmaceuticals \/ Xediton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Xediton Pharmaceuticals \/ Xediton Pharmaceuticals"},{"orgOrder":0,"company":"Xediton Pharmaceuticals","sponsor":"Quantum Genomics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Firibastat","moa":"Aminopeptidase A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Xediton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xediton Pharmaceuticals \/ Xediton Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Xediton Pharmaceuticals \/ Xediton Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Xediton Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Under the terms of the agreement, Xediton is responsible for the registration and commercialization of BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin) and VABOMERE® (meropenem and vaborbactam), four novel anti-infective produ...

                          Product Name : Baxdela

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          May 15, 2023

                          Lead Product(s) : Delafloxacin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Melinta Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Under the terms of the license and distribution agreement, Helsinn Healthcare SA grants Xediton an exclusive license to distribute, promote, market, and sell TRUSELTIQ in Canada and Helsinn will supply TRUSELTIQ for commercialization in Canada.

                          Product Name : Truseltiq

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 20, 2021

                          Lead Product(s) : Infigratinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Recipient : Helsinn Advanced Synthesis

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Under the terms of the agreement, Xediton Pharmaceuticals will receive exclusive commercialization rights to firibastat for the treatment of difficult to treat/resistant hypertension in Canada.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : $11.3 million

                          October 28, 2020

                          Lead Product(s) : Firibastat

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Recipient : Quantum Genomics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank